« Return to News | Drug Sponsors

Hikma to acquire the EPCI in Egypt

Friday, January 11, 2013 10:44 AM

Hikma Pharmaceuticals, a multinational pharmaceutical group, has agreed to acquire the Egyptian Company for Pharmaceuticals & Chemical Industries (EPCI) from a consortium of shareholders for an aggregate cash consideration of approximately $22.2 million.

The acquisition strengthens Hikma's position in the large and fast growing Egyptian market and adds a complementary portfolio of 35 products in 46 dosage forms and strengths, including three original cephalosporin anti–infective brands for the Egyptian market. The acquisition also adds a dedicated cephalosporin facility and an additional general formulation manufacturing plant in Egypt.

"Since we entered the Egyptian market in 2007, we have been rapidly growing our presence. This acquisition will further accelerate that growth, expanding our product portfolio and adding additional manufacturing capacity and technologies,” said Said Darwazah, CEO of Hikma. “We continue to strengthen our position as the leading regional manufacturer in MENA and to pursue other value–creating acquisition opportunities in the region."

The Egyptian pharmaceutical market is one of the largest and fastest growing MENA markets. According to IMS Health, the private retail market is valued at around $2.3 billion and grew by 10.6% in the 12 months prior to June 2012. Hikma Egypt is currently the seventeenth largest pharmaceutical manufacturer in Egypt, with an estimated market share of 1.6%.

Closing is expected to occur before February 14, 2013, and is conditional on fulfillment of conditions precedent.

HC Securities and Investment, the Cairo–based investment bank, acted as advisor to Hikma on this acquisition.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.